Santucci R. Joyce G. Wise M. et al.

Male urethral stricture disease.

J Urol. 177: 1667-1674Cotter K. Hahn A. Voelzke B. et al.

Trends in urethral stricture disease etiology and urethroplasty technique from a multi-institutional surgical outcomes research group.

Urology. 130: 167-174Hofer M. Morey A. Sheth K. et al.

Low serum testosterone level predisposes to artificial urinary sphincter cuff erosion.

Urology. 97: 245-249McKibben M. Fuentes J. Shakir N. et al.

Low serum testosterone is present in nearly half of men undergoing artificial urinary sphincter placement.

Urology. 118: 208-212Wolfe A. Ortiz N. Baumgarten A. et al.

Most men with artificial urinary sphincter cuff erosion have low serum testosterone levels.

Neurourol Urodyn. 40: 1035-1041Hofer M. Kapur P. Cordon B. et al.

Low testosterone levels result in decreased periurethral vascularity via an androgen receptor-mediated process: pilot study in urethral stricture tissue.

Urology. 105: 175-180Spencer J. Mahon J. Daugherty M. et al.

Hypoandrogenism is prevalent in males with urethral stricture disease and is associated with longer strictures.

Urology. 114: 218-223Johansson A. Rudolfsson S. Wikström P. et al.

Altered levels of angiopoietin 1 and tie 2 are associated with androgen-regulated vascular regression and growth in the ventral prostate in adult mice and rats.

Endocrinology. 146: 3463-3470Yura E. Bury M. Chan Y. et al.

Reversing urethral hypovascularity through testosterone and estrogen supplementation.

Urology. 146: 242-247Gerbie E. Bury M. Chan Y. et al.

Testosterone and Estrogen Repletion in a Hypogonadal Environment Improves Post-operative Angiogenesis.

Urology. 152: 9-e11Luo H. He L. Zhang G. et al.

Normal reference intervals of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and systemic immune inflammation index in healthy adults: a large multi-center study from Western China.

Clin Lab. 65: 255-265Gasparyan A. Ayvazyan L. Mukanova U. et al.

The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases.

Ann Lab Med. 39: 345-357Urkmez A. Topaktas R. Ozsoy E. et al.

Is neutrophil to lymphocyte ratio a predictive factor for recurrence of urethral stricture?.

Rev Assoc Med Bras. 65: 1448-1453Topaktaş R. Ürkmez A. Tokuç E. et al.

Hematologic parameters and neutrophil/lymphocyte ratio in the prediction of urethroplasty success.

Int Braz J Urol. 45: 369-375Autorino R. Damiano R. Di Lorenzo G. et al.

Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate.

Eur Urol. 55: 922-931

Urethral strictures and bipolar transurethral resection in saline of the prostate: fact or fiction?.

J Endourol. 24: 1333-1337Aydın A. Oltulu P. Balasar M. et al.

The role of prostate inflammation in the pathogenesis of urethral strictures occurring after transurethral resections.

Rev Int Androl. 20: 86-95

Factors predicting the development of urethral stricture after bipolar transurethral resection of the prostate.

Rev Assoc Med Bras. 68: 50-55Gül M. Altıntaş E. Kaynar M. et al.

The predictive value of platelet to lymphocyte and neutrophil to lymphocyte ratio in determining urethral stricture after transurethral resection of prostate.

Turk J Urol. 43: 325Sciarra A. Salciccia S. Albanesi L. et al.

Use of cyclooxygenase-2 inhibitor for prevention of urethral strictures secondary to transurethral resection of the prostate.

Urology. 66: 1218-1222

Lichen sclerosus: epidemiological distribution in an equal access health care system.

J Urol. 185: 522-525Kulkarni S. Barbagli G. Kirpekar D.

Lichen sclerosus of the male genitalia and urethra: surgical options and results in a multicenter international experience with 215 patients.

Eur Urol. 55: 945-956Erickson B. Elliott S. Myers J. et al.

Understanding the relationship between chronic systemic disease and lichen sclerosus urethral strictures.

J Urol. 195: 363-368Peterson A. Palminteri E. Lazzeri M. et al.

Heroic measures may not always be justified in extensive urethral stricture due to lichen sclerosus (balanitis xerotica obliterans).

Urology. 64: 565-568Sherman V. McPherson T. Baldo M. et al.

The high rate of familial lichen sclerosus suggests a genetic contribution: an observational cohort study.

J Eur Acad Dermatol Venereol. 24: 1031-1034Oyama N. Chan I. Neill S. et al.

Autoantibodies to extracellular matrix protein 1 in lichen sclerosus.

Lancet. 362: 118-123Levy A. Browne B. Fredrick A. et al.

Insights into the pathophysiology of urethral stricture disease due to lichen sclerosus: comparison of pathological markers in lichen sclerosus induced strictures vs nonlichen sclerosus induced strictures.

J Urol. 201: 1158-1163Kohli H. Childs B. Sullivan T.B. et al.

Differential expression of miRNAs involved in biological processes responsible for inflammation and immune response in lichen sclerosus urethral stricture disease.

PLoS One. 16: e0261505https://doi.org/10.1371/journal.pone.0261505Ren L. Zhao Y. Huo X. et al.

MiR-155-5p promotes fibroblast cell proliferation and inhibits FOXO signaling pathway in vulvar lichen sclerosis by targeting FOXO3 and CDKN1B.

Gene. 653: 43-50Levy A. Moynihan M. Bennett J. et al.

Protein Expression Profiles among Lichen Sclerosus Urethral Strictures—Can Urethroplasty Success be Predicted?.

J Urol. 203: 773-778Cohen A. Gaither T. Srirangapatanam S. et al.

Synchronous genitourinary lichen sclerosus signals a distinct urinary microbiome profile in men with urethral stricture disease.

World J Urol. 39: 605-611Sfanos K. Yegnasubramanian S. Nelson W. et al.

The inflammatory microenvironment and microbiome in prostate cancer development.

Nat Rev Urol. 15 (): 11-24Wei J. Calhoun E. Jacobsen S.

Urologic diseases in America project: benign prostatic hyperplasia.

J Urol. 173: 1256-1261Boyle P. Robertson C. Mazzetta C. et al.

The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study.

BJU Int. 92: 409-414

Could inflammation be a key component in the progression of benign prostatic hyperplasia?.

Cur Opin Urol. 16: 25-29Kramer G. Mitteregger D. Marberger M.

Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?.

Eur Urol. 51: 1202-1216McDowell K. Begley L. Mor-Vaknin N. et al.

Leukocytic promotion of prostate cellular proliferation.

Prostate. 70: 377-389Steiner G. Stix U. Handisurya A. et al.

Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue.

Lab Invest. 83: 1131-1146Delongchamps N. de la Roza G. Chandan V. et al.

Evaluation of prostatitis in autopsied prostates—is chronic inflammation more associated with benign prostatic hyperplasia or cancer?.

J Urol. 179: 1736-1740Nickel J. Roehrborn C. O'Leary M. et al.

The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial.

Eur Urol. 54: 1379-1384

The human cytokine I-309 is a monocyte chemoattractant.

Proc Natl Acad Sci. 89: 2950-2954Zingoni A. Soto H. Hedrick J. et al.

Cutting edge: the chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells.

J Immunol. 161: 547-551Roos R. Loetscher M. Legler D. et al.

Identification of CCR8, the receptor for the human CC chemokine I-309.

J Biol Chem. 272: 17251-17254Agarwal M. He C. Siddiqui J. et al.

CCL11 (eotaxin-1): A new diagnostic serum marker for prostate cancer.

Prostate. 73: 573-581Penna G. Mondaini N. Amuchastegui S. et al.

Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.

Eur Urol. 51: 524-533Milasheuski P. Nitkin D. Gres A. et al.

Immunological status biomarkers as the risk factors of BPH progression.

Eur Urol Supp. 18: e2494-e2495Schenk J. Kristal A. Neuhouser M. et al.

Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Am J Epidemiol. 171: 571-582Fowke J. Koyama T. Fadare O. et al.

Does inflammation mediate the obesity and BPH relationship? An epidemiologic analysis of body composition and inflammatory markers in blood, urine, and prostate tissue, and the relationship with prostate enlargement and lower urinary tract symptoms.

PloS one. 11: e0156918Anukam K. Hayes K. Summers K. et al.

Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 may help downregulate TNF-Alpha, IL-6, IL-8, IL-10 and IL-12 (p70) in the neurogenic bladder of spinal cord injured patient with urinary tract infections: a two-case study.

Adv Urol. 2009: 680363Kim J. Seo S. Park Y. et al.

Changes in detrusor and urinary growth factors according to detrusor function after partial bladder outlet obstruction in the rat.

Urology. 57: 371-375Shi B. Zhu Y. Laudon V. et al.

Alterations of urine tgf-β1 and bFGF following bladder outlet obstruction: a predictor for detrusor contractibility?.

Urol Int. 82: 43-47Monga M. Gabal-Shehab L. Stein P.

Urinary transforming growth factor-β1 levels correlate with bladder outlet obstruction.

Int J Urol. 8: 487-489Mitterberger M. Pallwein L. Gradl J. et al.

Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder.

BJU Int. 99: 831-835de Jongh R. Dambros M. Haenen G. et al.

Partial bladder outlet obstruction reduces the tissue antioxidant capacity and muscle nerve density of the guinea pig bladder.

Neurourol Urodyn. 28: 461-467Lin W. Chen C. Wu S. et al.

Oxidative stress biomarkers in urine and plasma of rabbits with partial bladder outlet obstruction.

BJU Int. 107: 1839-1843Lin W. Wu S. Lin Y. et al.

Reversing bladder outlet obstruction attenuates systemic and tissue oxidative stress.

BJU Int. 110: 1208-1213Clayton D. Stephany H. Ching C. et al.

F2-isoprostanes as a biomarker of oxidative stress in the mouse bladder.

J Urol. 191: 1597-1601Roehrborn C. Boyle P. Gould A. et al.

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.

Urology. 53: 581-589Wright E. Fang J. Metter E. et al.

Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging.

J Urol. 167: 2484-2487Pinsky P. Kramer B. Crawford E. et al.

Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial.

Urology. 68: 352-356Lilja H. Ulmert D. Vickers A.

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

Nat Rev Cancer. 8: 268-728

Urinary bladder urothelium: molecular sensors of chemical/thermal/mechanical stimuli.

Vasc Pharm. 45: 221-226Wang E. Lee J. Ruiz W. et al.

ATP and purinergic receptor–dependent membrane traffic in bladder umbrella cells.

J Clin Invest. 115: 2412-2422Silva-Ramos M. Silva I. Oliveira J. et al.

Increased urinary adenosine triphosphate in patients with bladder outlet obstruction due to benign prostate hyperplasia.

Prostate. 76: 1353-1363Gill K. Horsley H. Kupelian A. et al.

Urinary ATP as an indicator of infection and inflammation of the urinary tract in patients with lower urinary tract symptoms.

BMC Urol. 15: 1-9

Neurotrophins in bladder function: what do we know and where do we go from here?.

Neurourol Urodyn. 33: 39-45

Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders.

Nat Clin Pract Urol. 3: 101-110

Mechanisms involved in new therapies for overactive bladder.

Urology. 63: 65-73Ochodnický P. Cruz C. Yoshimura N. et al.

Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target.

Neurourol Urodyn. 30: 1227-1241

Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment.

Urology. 72: 104-108Wada N. Matsumoto S. Kita M. et al.

Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.

Int J Urol. 21: 1258-1262Coyne K. Sexton C. Vats V. et al.

National community prevalence of overactive bladder in the United States stratified by sex and age.

Urology. 77: 1081-1087Peyronnet B. Mironska E. Chapple C. et al.

A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment.

Eur Urol. 75: 988-1000Silva-Ramos M. Silva I. Oliveira O. et al.

Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome.

PloS one. 8: e64696

A pilot study to investigate the associations of urinary concentrations of NO, ATP and derivatives with overactive bladder symptom severity.

Exp Physiol. 105: 932-939Sugaya K. Nishijima S. Kadekawa K. et al.

Relationship between lower urinary tract symptoms and urinary ATP in patients with benign prostatic hyperplasia or overactive bladder.

Biomed Res J. 30: 287-294Tsiapakidou S. Apostolidis A. Pantazis K. et al.

The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis.

Int Urogyn J. 7: 1-3Kuo H. Hsin-Tzu L. Chancellor M.

Can urinary nerve growth factor be a biomarker for overactive bladder?.

Rev Urol. 12: e69Alkis O. Zumrutbas A. Toktas C. et al.

The use of biomarkers in the diagnosis and treatment of overactive bladder: Can we predict the patients who will be resistant to treatment?.

Neurourol Urodyn. 36: 390-393